O	0	5	Mouse	Mouse	NN	B-NP
O	6	9	p10	p10	NN	I-NP
O	9	10	,	,	,	O
O	11	13	an	an	DT	B-NP
O	14	25	alternative	alternative	JJ	I-NP
O	26	33	spliced	splice	VBN	I-NP
O	34	38	form	form	NN	I-NP
O	39	41	of	of	IN	B-PP
O	42	50	p15INK4b	p15INK4b	NN	B-NP
O	50	51	,	,	,	O
O	52	60	inhibits	inhibit	VBZ	B-VP
B-Cell	61	65	cell	cell	NN	B-NP
O	66	71	cycle	cycle	NN	I-NP
O	72	83	progression	progression	NN	I-NP
O	84	87	and	and	CC	O
O	88	97	malignant	malignant	JJ	B-NP
O	98	112	transformation	transformation	NN	I-NP
O	112	113	.	.	.	O

O	115	118	The	The	DT	B-NP
O	119	123	INK4	INK4	NN	I-NP
O	124	130	family	family	NN	I-NP
O	131	133	of	of	IN	B-PP
O	134	142	proteins	protein	NNS	B-NP
O	143	153	negatively	negatively	RB	B-VP
O	154	163	regulates	regulate	VBZ	I-VP
B-Cell	164	168	cell	cell	NN	B-NP
O	169	174	cycle	cycle	NN	I-NP
O	175	186	progression	progression	NN	I-NP
O	187	189	at	at	IN	B-PP
O	190	193	the	the	DT	B-NP
O	194	195	G	G	NN	I-NP
O	195	196	(	(	(	O
O	196	197	1	1	CD	B-NP
O	197	198	)	)	)	O
O	198	199	-	-	HYPH	B-NP
O	199	200	S	S	NN	I-NP
O	201	211	transition	transition	NN	I-NP
O	212	214	by	by	IN	B-PP
O	215	225	inhibiting	inhibit	VBG	B-VP
O	226	232	cyclin	cyclin	NN	B-NP
O	232	233	-	-	HYPH	B-NP
O	233	242	dependent	dependent	JJ	I-NP
O	243	250	kinases	kinase	NNS	I-NP
O	250	251	.	.	.	O

O	252	255	Two	Two	CD	B-NP
O	256	258	of	of	IN	B-PP
O	259	264	these	these	DT	B-NP
B-Cell	265	269	cell	cell	NN	I-NP
O	270	275	cycle	cycle	NN	I-NP
O	276	286	inhibitors	inhibitor	NNS	I-NP
O	286	287	,	,	,	O
O	288	291	p16	p16	NN	B-NP
O	291	292	(	(	(	O
O	292	297	INK4A	INK4A	NN	B-NP
O	297	298	)	)	)	O
O	299	302	and	and	CC	O
O	303	306	p15	p15	NN	B-NP
O	306	307	(	(	(	O
O	307	312	INK4B	INK4B	NN	B-NP
O	312	313	)	)	)	O
O	313	314	,	,	,	O
O	315	319	have	have	VBP	B-VP
B-Cancer	320	325	tumor	tumor	NN	B-NP
O	326	336	suppressor	suppressor	NN	I-NP
O	337	347	activities	activity	NNS	I-NP
O	348	351	and	and	CC	O
O	352	355	are	be	VBP	B-VP
O	356	367	inactivated	inactivate	VBN	I-VP
O	368	370	in	in	IN	B-PP
O	371	376	human	human	JJ	B-NP
B-Cancer	377	383	cancer	cancer	NN	I-NP
O	383	384	.	.	.	O

O	385	398	Interestingly	Interestingly	RB	B-ADVP
O	398	399	,	,	,	O
O	400	404	both	both	DT	B-NP
O	405	409	INK4	INK4	NN	I-NP
O	410	415	genes	gene	NNS	I-NP
O	416	423	express	express	VBP	B-VP
O	424	435	alternative	alternative	JJ	B-NP
O	436	444	splicing	splicing	NN	I-NP
O	445	453	variants	variant	NNS	I-NP
O	453	454	.	.	.	O

O	455	457	In	In	IN	B-PP
O	458	466	addition	addition	NN	B-NP
O	467	469	to	to	TO	B-PP
O	470	473	p16	p16	NN	B-NP
O	473	474	(	(	(	O
O	474	479	INK4A	INK4A	NN	B-NP
O	479	480	)	)	)	O
O	480	481	,	,	,	O
O	482	485	the	the	DT	B-NP
O	486	491	INK4A	INK4A	NN	I-NP
O	492	497	locus	locus	NN	I-NP
O	498	505	encodes	encode	VBZ	B-VP
O	506	507	a	a	DT	B-NP
O	508	514	splice	splice	NN	I-NP
O	515	522	variant	variant	NN	I-NP
O	522	523	,	,	,	O
O	524	530	termed	term	VBN	B-NP
O	531	534	p12	p12	NN	I-NP
O	534	535	-	-	HYPH	O
O	535	536	-	-	HYPH	B-NP
O	536	548	specifically	specifically	RB	B-VP
O	549	558	expressed	express	VBN	I-VP
O	559	561	in	in	IN	B-PP
O	562	567	human	human	JJ	B-NP
B-Organ	568	576	pancreas	pancreas	NN	I-NP
O	576	577	-	-	HYPH	O
O	577	578	-	-	HYPH	O
O	578	581	and	and	CC	O
O	582	585	ARF	ARF	NN	B-NP
O	585	586	,	,	,	O
O	587	588	a	a	DT	B-NP
O	589	596	protein	protein	NN	I-NP
O	597	604	encoded	encode	VBN	B-VP
O	605	607	by	by	IN	B-PP
O	608	610	an	an	DT	B-NP
O	611	622	alternative	alternative	JJ	I-NP
O	623	630	reading	reading	NN	I-NP
O	631	636	frame	frame	NN	I-NP
O	637	641	that	that	WDT	B-NP
O	642	646	acts	act	VBZ	B-VP
O	647	649	as	as	IN	B-PP
O	650	651	a	a	DT	B-NP
B-Cancer	652	657	tumor	tumor	NN	I-NP
O	658	668	suppressor	suppressor	NN	I-NP
O	669	676	through	through	IN	B-PP
O	677	680	the	the	DT	B-NP
O	681	684	p53	p53	NN	I-NP
O	685	692	pathway	pathway	NN	I-NP
O	692	693	.	.	.	O

O	694	703	Similarly	Similarly	RB	B-ADVP
O	703	704	,	,	,	O
O	705	708	the	the	DT	B-NP
O	709	714	human	human	JJ	I-NP
O	715	720	INK4B	INK4B	NN	I-NP
O	721	726	locus	locus	NN	I-NP
O	727	734	encodes	encode	VBZ	B-VP
O	735	738	the	the	DT	B-NP
O	739	742	p15	p15	NN	I-NP
O	742	743	(	(	(	O
O	743	748	INK4B	INK4B	NN	B-NP
O	748	749	)	)	)	O
B-Cancer	750	755	tumor	tumor	NN	B-NP
O	756	766	suppressor	suppressor	NN	I-NP
O	767	770	and	and	CC	O
O	771	774	one	one	CD	B-NP
O	775	788	alternatively	alternatively	RB	I-NP
O	789	796	spliced	splice	VBN	I-NP
O	797	801	form	form	NN	I-NP
O	801	802	,	,	,	O
O	803	809	termed	term	VBN	B-VP
O	810	812	as	as	IN	B-PP
O	813	816	p10	p10	NN	B-NP
O	816	817	.	.	.	O

O	818	820	We	We	PRP	B-NP
O	821	825	show	show	VBP	B-VP
O	826	830	here	here	RB	B-ADVP
O	831	835	that	that	IN	B-SBAR
O	836	839	p10	p10	NN	B-NP
O	839	840	,	,	,	O
O	841	846	which	which	WDT	B-NP
O	847	853	arises	arise	VBZ	B-VP
O	854	858	from	from	IN	B-PP
O	859	862	the	the	DT	B-NP
O	863	866	use	use	NN	I-NP
O	867	869	of	of	IN	B-PP
O	870	872	an	an	DT	B-NP
O	873	884	alternative	alternative	JJ	I-NP
O	885	891	splice	splice	NN	I-NP
O	892	897	donor	donor	NN	I-NP
O	898	902	site	site	NN	I-NP
O	903	909	within	within	IN	B-PP
B-Cellular_component	910	916	intron	intron	NN	B-NP
I-Cellular_component	917	918	1	1	CD	I-NP
O	918	919	,	,	,	O
O	920	922	is	be	VBZ	B-VP
O	923	932	conserved	conserve	VBN	I-VP
O	933	935	in	in	IN	B-PP
O	936	939	the	the	DT	B-NP
O	940	945	mouse	mouse	NN	I-NP
O	946	952	genome	genome	NN	I-NP
O	953	956	and	and	CC	O
O	957	959	is	be	VBZ	B-VP
O	960	966	widely	widely	RB	I-VP
O	967	976	expressed	express	VBN	I-VP
O	977	979	in	in	IN	B-PP
O	980	985	mouse	mouse	NN	B-NP
B-Tissue	986	993	tissues	tissue	NNS	I-NP
O	993	994	.	.	.	O

O	995	1004	Similarly	Similarly	RB	B-ADVP
O	1005	1007	to	to	TO	B-PP
O	1008	1013	mouse	mouse	NN	B-NP
O	1014	1017	p15	p15	NN	I-NP
O	1017	1018	(	(	(	O
O	1018	1023	INK4B	INK4B	NN	B-NP
O	1023	1024	)	)	)	O
O	1024	1025	,	,	,	O
O	1026	1029	p10	p10	NN	B-NP
O	1030	1040	expression	expression	NN	I-NP
O	1041	1043	is	be	VBZ	B-VP
O	1044	1048	also	also	RB	I-VP
O	1049	1056	induced	induce	VBN	I-VP
O	1057	1059	by	by	IN	B-PP
O	1060	1069	oncogenic	oncogenic	JJ	B-NP
O	1070	1077	insults	insult	NNS	I-NP
O	1078	1081	and	and	CC	O
O	1082	1094	transforming	transform	VBG	B-VP
O	1095	1101	growth	growth	NN	B-NP
O	1102	1108	factor	factor	NN	I-NP
O	1108	1109	-	-	HYPH	O
O	1109	1113	beta	beta	SYM	B-NP
O	1114	1123	treatment	treatment	NN	B-NP
O	1124	1127	and	and	CC	O
O	1128	1132	acts	act	VBZ	B-VP
O	1133	1135	as	as	IN	B-PP
O	1136	1137	a	a	DT	B-NP
B-Cell	1138	1142	cell	cell	NN	I-NP
O	1143	1148	cycle	cycle	NN	I-NP
O	1149	1158	inhibitor	inhibitor	NN	I-NP
O	1158	1159	.	.	.	O

O	1160	1171	Importantly	Importantly	RB	B-ADVP
O	1171	1172	,	,	,	O
O	1173	1175	we	we	PRP	B-NP
O	1176	1180	show	show	VBP	B-VP
O	1181	1185	that	that	IN	B-SBAR
O	1186	1191	mouse	mouse	NN	B-NP
O	1192	1195	p10	p10	NN	I-NP
O	1196	1198	is	be	VBZ	B-VP
O	1199	1203	able	able	JJ	B-ADJP
O	1204	1206	to	to	TO	B-VP
O	1207	1213	induce	induce	VB	I-VP
B-Cell	1214	1218	cell	cell	NN	B-NP
O	1219	1224	cycle	cycle	NN	I-NP
O	1225	1231	arrest	arrest	NN	I-NP
O	1232	1234	in	in	IN	B-PP
O	1235	1236	a	a	DT	B-NP
O	1237	1240	p53	p53	NN	I-NP
O	1240	1241	-	-	HYPH	B-NP
O	1241	1250	dependent	dependent	JJ	I-NP
O	1251	1257	manner	manner	NN	I-NP
O	1257	1258	.	.	.	O

O	1259	1261	We	We	PRP	B-NP
O	1262	1266	also	also	RB	B-ADVP
O	1267	1271	show	show	VBP	B-VP
O	1272	1276	that	that	IN	B-SBAR
O	1277	1282	mouse	mouse	NN	B-NP
O	1283	1286	p10	p10	NN	I-NP
O	1287	1289	is	be	VBZ	B-VP
O	1290	1294	able	able	JJ	B-ADJP
O	1295	1297	to	to	TO	B-VP
O	1298	1305	inhibit	inhibit	VB	I-VP
B-Cell	1306	1310	foci	focus	NNS	B-NP
O	1311	1320	formation	formation	NN	I-NP
O	1321	1324	and	and	CC	I-NP
O	1325	1334	anchorage	anchorage	NN	I-NP
O	1334	1335	-	-	HYPH	B-NP
O	1335	1346	independent	independent	JJ	I-NP
O	1347	1353	growth	growth	NN	I-NP
O	1354	1356	in	in	IN	B-PP
O	1357	1361	wild	wild	JJ	B-NP
O	1361	1362	-	-	HYPH	I-NP
O	1362	1366	type	type	NN	I-NP
O	1367	1372	mouse	mouse	NN	I-NP
B-Cell	1373	1382	embryonic	embryonic	JJ	I-NP
I-Cell	1383	1394	fibroblasts	fibroblast	NNS	I-NP
O	1394	1395	,	,	,	O
O	1396	1399	and	and	CC	O
O	1400	1404	that	that	IN	B-SBAR
O	1405	1410	these	these	DT	B-NP
O	1411	1427	antitransforming	antitransforming	JJ	I-NP
O	1428	1438	properties	property	NNS	I-NP
O	1439	1441	of	of	IN	B-PP
O	1442	1447	mouse	mouse	NN	B-NP
O	1448	1451	p10	p10	NN	I-NP
O	1452	1455	are	be	VBP	B-VP
O	1456	1460	also	also	RB	B-ADVP
O	1461	1464	p53	p53	NN	B-ADJP
O	1464	1465	-	-	HYPH	I-ADJP
O	1465	1474	dependent	dependent	JJ	B-ADJP
O	1474	1475	.	.	.	O

O	1476	1481	These	These	DT	B-NP
O	1482	1489	results	result	NNS	I-NP
O	1490	1498	indicate	indicate	VBP	B-VP
O	1499	1503	that	that	IN	B-SBAR
O	1504	1507	the	the	DT	B-NP
O	1508	1513	INK4B	INK4B	NN	I-NP
O	1514	1519	locus	locus	NN	I-NP
O	1519	1520	,	,	,	O
O	1521	1530	similarly	similarly	RB	B-ADVP
O	1531	1533	to	to	TO	B-PP
O	1534	1539	INK4A	INK4A	NN	B-NP
O	1539	1540	-	-	HYPH	B-NP
O	1540	1543	ARF	ARF	NN	I-NP
O	1543	1544	,	,	,	O
O	1545	1552	harbors	harbor	VBZ	B-VP
O	1553	1556	two	two	CD	B-NP
O	1557	1566	different	different	JJ	I-NP
O	1567	1575	splicing	splicing	NN	I-NP
O	1576	1584	variants	variant	NNS	I-NP
O	1585	1589	that	that	WDT	B-NP
O	1590	1593	can	can	MD	B-VP
O	1594	1596	be	be	VB	I-VP
O	1597	1605	involved	involve	VBN	I-VP
O	1606	1608	in	in	IN	B-PP
O	1609	1612	the	the	DT	B-NP
O	1613	1623	regulation	regulation	NN	I-NP
O	1624	1626	of	of	IN	B-PP
O	1627	1631	both	both	CC	O
O	1632	1635	the	the	DT	B-NP
O	1636	1639	p53	p53	NN	I-NP
O	1640	1643	and	and	CC	I-NP
O	1644	1658	retinoblastoma	retinoblastoma	NN	I-NP
O	1659	1667	pathways	pathway	NNS	I-NP
O	1667	1668	,	,	,	O
O	1669	1672	the	the	DT	B-NP
O	1673	1676	two	two	CD	I-NP
O	1677	1682	major	major	JJ	I-NP
O	1683	1692	molecular	molecular	JJ	I-NP
O	1693	1701	pathways	pathway	NNS	I-NP
O	1702	1704	in	in	IN	B-PP
B-Cancer	1705	1710	tumor	tumor	NN	B-NP
O	1711	1722	suppression	suppression	NN	I-NP
O	1722	1723	.	.	.	O

